SCL Science Inc. (KOSDAQ:246960)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,799.00
-61.00 (-3.28%)
At close: Mar 9, 2026
-14.84%
Market Cap 61.20B
Revenue (ttm) 16.32B
Net Income (ttm) -3.66B
Shares Out 34.02M
EPS (ttm) -123.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 60,024
Average Volume 77,646
Open 1,857.00
Previous Close 1,860.00
Day's Range 1,770.00 - 1,857.00
52-Week Range 1,770.00 - 5,110.00
Beta 0.69
RSI 34.59
Earnings Date Mar 20, 2026

About SCL Science

SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasis and sealing products; STOP, a non-bleeding intravascular injection; Film that prevents leakage at intestinal and vascular anastomosis sites; InnoLOCK... [Read more]

Industry Orthopedic, Prosthetic, and Surgical Appliances and Supplies
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 246960
Full Company Profile

Financial Performance

In 2024, SCL Science's revenue was 4.74 billion, an increase of 258.30% compared to the previous year's 1.32 billion. Losses were -3.73 billion, -25.79% less than in 2023.

Financial Statements

News

There is no news available yet.